AR122175A1 - Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina - Google Patents

Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina

Info

Publication number
AR122175A1
AR122175A1 ARP210101422A ARP210101422A AR122175A1 AR 122175 A1 AR122175 A1 AR 122175A1 AR P210101422 A ARP210101422 A AR P210101422A AR P210101422 A ARP210101422 A AR P210101422A AR 122175 A1 AR122175 A1 AR 122175A1
Authority
AR
Argentina
Prior art keywords
dosage forms
oral dosage
solid oral
gonadotropin
combination
Prior art date
Application number
ARP210101422A
Other languages
English (en)
Spanish (es)
Inventor
David E Alonzo
Kathleen D Ullmer
Minli Xie
Original Assignee
Myovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myovant Sciences Gmbh filed Critical Myovant Sciences Gmbh
Publication of AR122175A1 publication Critical patent/AR122175A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
ARP210101422A 2020-05-29 2021-05-27 Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina AR122175A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063032469P 2020-05-29 2020-05-29

Publications (1)

Publication Number Publication Date
AR122175A1 true AR122175A1 (es) 2022-08-24

Family

ID=76305879

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101422A AR122175A1 (es) 2020-05-29 2021-05-27 Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina

Country Status (18)

Country Link
US (1) US12551447B2 (https=)
EP (1) EP4157227A1 (https=)
JP (1) JP2023528014A (https=)
KR (1) KR20230028732A (https=)
CN (1) CN115666531B (https=)
AR (1) AR122175A1 (https=)
AU (1) AU2021278303A1 (https=)
BR (1) BR112022023937A2 (https=)
CA (1) CA3185151A1 (https=)
CL (1) CL2022003338A1 (https=)
CO (1) CO2022019160A2 (https=)
EC (1) ECSP22098275A (https=)
IL (1) IL298587A (https=)
MX (1) MX2022015003A (https=)
PE (1) PE20230859A1 (https=)
PY (1) PY2142442A (https=)
UY (1) UY39229A (https=)
WO (1) WO2021239917A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
CN115227648B (zh) * 2022-08-03 2023-09-29 南昌大学 一种瑞卢戈利固体自微乳及其制备方法和应用
CN115068421B (zh) * 2022-08-03 2023-08-04 南昌大学 一种瑞卢戈利纳米混悬液及其制备方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
TW284688B (https=) 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
FR2710637B1 (fr) 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
JP3854648B2 (ja) 1994-04-19 2006-12-06 武田薬品工業株式会社 縮合チオフェン誘導体、その製造法及び用途
ECSP961635A (es) 1996-01-11 1997-06-27 Desprendimiento controlado de esteroides del recubrimiento de azucar
ECSP971998A (es) 1997-01-15 1998-04-07 Desprendimiento controlado de esteroides del recubrimiento de azucar
DE19815060A1 (de) 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
KR20030005205A (ko) 2000-02-29 2003-01-17 다케다 야쿠힌 고교 가부시키가이샤 티에노피리미딘 유도체의 제조 방법
JP5072166B2 (ja) 2002-01-30 2012-11-14 武田薬品工業株式会社 チエノピリミジン化合物、その製造法および用途
US7569570B2 (en) 2002-01-30 2009-08-04 Takeda Pharmaceutical Company Limited Thienopyrimidines, process for preparing the same and use thereof
BRPI0307786B8 (pt) 2002-02-26 2021-05-25 Astrazeneca Ab composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água
EP1591446B1 (en) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
JP4039574B2 (ja) 2003-01-29 2008-01-30 武田薬品工業株式会社 チエノピリミジン化合物およびその用途
PE20130200A1 (es) 2003-04-08 2013-03-09 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
AU2004257639B2 (en) 2003-07-07 2011-01-06 Neurocrine Biosciences, Inc. Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
KR20080041662A (ko) 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
EP2155194B1 (en) 2007-04-06 2015-01-21 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
EP2329823A4 (en) 2008-09-03 2013-04-03 Takeda Pharmaceutical PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EA026675B1 (ru) 2010-06-16 2017-05-31 Эндорешерш, Инк. Способы лечения или предотвращения эстрогензависимых заболеваний
JP2012077020A (ja) 2010-09-30 2012-04-19 Mochida Pharmaceut Co Ltd ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
PL2900675T3 (pl) 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
PL2945628T3 (pl) 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
CA2978223A1 (en) 2015-02-26 2016-09-01 Takeda Pharmaceutical Company Limited Formulations of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
US9949974B2 (en) 2015-09-01 2018-04-24 Abbvie Inc. Methods of adminstering elagolix
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
CN110248661A (zh) 2016-09-30 2019-09-17 梦欧文科学有限责任公司 前列腺癌的治疗
SG11201911598WA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
SG11202104053TA (en) * 2018-11-07 2021-05-28 ObsEva SA Compositions and methods for the treatment of estrogen-dependent disorders
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
EP4041738A1 (en) 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Also Published As

Publication number Publication date
PY2142442A (es) 2022-12-30
BR112022023937A2 (pt) 2022-12-27
IL298587A (en) 2023-01-01
AU2021278303A1 (en) 2023-02-09
EP4157227A1 (en) 2023-04-05
CL2022003338A1 (es) 2023-06-30
WO2021239917A1 (en) 2021-12-02
ECSP22098275A (es) 2023-01-31
US20230165800A1 (en) 2023-06-01
KR20230028732A (ko) 2023-03-02
UY39229A (es) 2021-12-31
US12551447B2 (en) 2026-02-17
JP2023528014A (ja) 2023-07-03
CA3185151A1 (en) 2021-12-02
CO2022019160A2 (es) 2023-03-27
CN115666531A (zh) 2023-01-31
CN115666531B (zh) 2025-08-19
PE20230859A1 (es) 2023-05-30
MX2022015003A (es) 2023-03-03

Similar Documents

Publication Publication Date Title
AR122175A1 (es) Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina
AR109816A2 (es) Forma de dosificación farmacéutica para administración oral de un inhibidor de la familia bcl-2
ECSP055569A (es) Forma de dosificación de pramipexol en una dosis única diaria
EA202191061A1 (ru) фармацевтическая композиция для перорального введения, содержащая диметиламинA или его соль
IT1271495B (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi
JP2009541443A5 (https=)
CL2007000601A1 (es) Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
BRPI0519171A2 (pt) dispositivo de administraÇço de medicamento oftÁlmico
DOP2013000169A (es) Compuesto para uso en el tratamiento de la artritis
BR112019006228A2 (pt) tratamento de câncer de próstata
BR112023026909A2 (pt) Sal farmaceuticamente aceitável de ap1189 ((e)-n-[1-(2-nitrofenil)-1-h-pirrol-2-il-alilidenoamino]-guanidina), composição farmacêutica, forma de dosagem única, e, formulação oral
SE0302488D0 (sv) New combination
ATE442158T1 (de) Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
MY208267A (en) Oral pharmaceutical composition containing heterocyclic compound
EA201101119A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
AR038858A1 (es) Combinacion
AR045330A1 (es) Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
EA200500672A1 (ru) Содержащие альфузозин композиции с отсроченным высвобождением
NI200600270A (es) Una composición farmacéutica antimicobacteriana que comprende un farmaco antituberculosis
CL2008001176A1 (es) Combinacion farmaceutica que comprende pregabalina y 1-(2-etoxietil)-5-[etil(metil)amino]-n-mesil-7-[(4-metil-2-piridil)amino]-1h-pirazol[4,3-d]pirimidina-3-carboxamida; composicion farmaceutica; y uso de la combinacion para el tratamiento del dolor.
CU23370A3 (es) Forma de dosis oral que contiene un inhibidor de pde 4 como un ingrediente activo y polivinilpirrolidona como excipiente
FI4079306T3 (fi) BTK-estäjä käytettäväksi IgA-nefropatian tai purppura nefriitin hoidossa
AR077501A1 (es) Una composicion farmaceutica unitaria, administrable por via oral, que comprende la combinacion de los compuestos (alfa s)-n,n-dimetil-alfa-[2-(1-naftaleniloxi)etil]benzeno-metanamina y 1-[[3-(4,7-dihidro-1-metil-7-oxo-3-propil-1h-pirazolo[4,3-d]pirimidin-5-il)-4-etoxifenil]sulfonil]-4-metilpiperazi
UY28499A1 (es) Tratamiento terapéutico